• Product name
    Anti-TRAIL antibody [75411.11]
    See all TRAIL primary antibodies
  • Description
    Mouse monoclonal [75411.11] to TRAIL
  • Host species
  • Tested applications
    Suitable for: IHC-P, Neutralising, Inhibition Assay, ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Recombinant full length protein (Human).

  • General notes

    Abcam is committed to meeting high standards of ethical manufacturing and has decided to discontinue this product by June 2019 as it has been generated by the ascites method. We are sorry for any inconvenience this may cause. We would recommend antibody ab9959 as a replacement.



Our Abpromise guarantee covers the use of ab10516 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 8 - 25 µg/ml.
Neutralising Use at an assay dependent concentration.

To measure the ability of this antibody to neutralize the biological activity of TRAIL, cross-linked recombinant human TRAIL is incubated with various concentrations of the antibody for 1 hour at 37°C in a 96 well plate. Following this preincubation period, mouse L929 cells are added. The assay mixture in a total volume of 150 µl per well, containing antibody at concentrations of 0.01-100 ng/ml, cross-linked recombinant human TRAIL at 12 ng/ml and actinomycin D at 1 µg/ml, are incubated at 37°C for 24 hours in a humidified CO2 incubator. Following incubation, the cells are fixed with 5% formaldehyde and then stained with a crystal violet solution containing 100 µl of 33% acetic acid. Absorbance at 540 nm is read on a microplate reader. The exact concentration of antibody required to neutralize TRAIL is dependent on the cytokine concentration, cell type, growth conditions and the ty

Inhibition Assay Use a concentration of 0.02 - 0.08 µg/ml.

The Neutralization Dose50 (ND50) for this antibody is defined as that concentration required to yield one-half maximal inhibition of the TRAIL-mediated activity on a responsive cell line, when TRAIL is present at a concentration high enough to elicit a maximum response. Monoclonal anti-TRAIL (APO-2L) has the ability to neutralize the biological activity of recombinant human TRAIL. The ND50 for this effect is approximately 2-8 ng/ml in the presence of 12 ng/ml of cross-linked recombinant human TRAIL, using mouse L929 cells.

ELISA Use a concentration of 0.5 - 1 µg/ml.

Concentration determined using 25ng/well recombinant human TRAIL.

WB Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 24 kDa (predicted molecular weight: 33.7 kDa). PubMed: 21419121

Determined using human TRAIL at approximately 50 ng/lane under non-reducing and reducing conditions. 


  • Function
    Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
  • Tissue specificity
    Widespread; most predominant in spleen, lung and prostate.
  • Sequence similarities
    Belongs to the tumor necrosis factor family.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • Apo 2 ligand antibody
    • APO 2L antibody
    • Apo-2 ligand antibody
    • Apo-2L antibody
    • APO2L antibody
    • CD253 antibody
    • CD253 antigen antibody
    • Chemokine tumor necrosis factor ligand superfamily member 10 antibody
    • Protein TRAIL antibody
    • TL2 antibody
    • TNF Related Apoptosis Inducing Ligand antibody
    • TNF related apoptosis inducing ligand TRAIL antibody
    • TNF-related apoptosis-inducing ligand antibody
    • TNF10_HUMAN antibody
    • TNFSF10 antibody
    • TRAIL antibody
    • Tumor necrosis factor (ligand) family member 10 antibody
    • Tumor Necrosis Factor (ligand) Superfamily Member 10 antibody
    • Tumor necrosis factor apoptosis inducing ligand splice variant delta antibody
    • Tumor necrosis factor ligand superfamily member 10 antibody
    see all


This product has been referenced in:
  • Wang MS  et al. Iron oxide magnetic nanoparticles combined with actein suppress non-small-cell lung cancer growth in a p53-dependent manner. Int J Nanomedicine 12:7627-7651 (2017). WB ; Human . Read more (PubMed: 29089760) »
  • Sambandam Y  et al. Vitamin D Modulation of TRAIL Expression in Human Milk and Mammary Epithelial Cells. Sci Rep 7:4362 (2017). WB ; Human . Read more (PubMed: 28659589) »

See all 5 Publications for this product

Customer reviews and Q&As

I can confirm that our products are sterile and ab10516 also contains sodium azide and thimerisol as preservatives to keep the antibody sterile after opening. The preservatives are in a low concentration and should therefore not interfere with exper...

Read More

That is no problem. If you do have any further questions, please do not hesitate to contact us again.

Until then, I wish you all the best with your research.

Thank you for your reply.

The BSA is added to the antibody buffer improve long term storage. If you are making up a diluted solution to use in your assays you should not need to add BSA as long as you are not intending to store the solution f...

Read More

Thank you for contacting us and your interest in our products.

We have information that this antibody has inhibition activity from the following reference:

Roux S et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tu...

Read More

Nous sommes désolés d'apprendre que l'anticorps ab10516 n'a pas fonctionné comme attendu. Je me permets de vous informer à nouveau que nos produits sont garantis pour fonctionner tels qu'ils sont décrits sur la fiche ...

Read More

Thank you for your email. We do not routinely offer free or trial sized samples for testing purposes. Our policy at Abcam is that if an antibody does not work as specified on the datasheet, we will offer a replacement or reimbursement. Should you d...

Read More


Sign up